Cargando…
EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry
BACKGROUND: Arterial hypertension is highly prevalent but poorly controlled. Blood pressure (BP) reduction substantially reduces cardiovascular morbidity and mortality. Recent randomized, double-blind clinical trials demonstrated that azilsartan medoxomil (AZM) is more effective in reducing BP than...
Autores principales: | Gitt, Anselm K, Baumgart, Peter, Bramlage, Peter, Mahfoud, Felix, Potthoff, Sebastian A, Senges, Jochen, Schneider, Steffen, Buhck, Hartmut, Schmieder, Roland E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706336/ https://www.ncbi.nlm.nih.gov/pubmed/23819631 http://dx.doi.org/10.1186/1471-2261-13-46 |
Ejemplares similares
-
Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry
por: Gitt, Anselm K., et al.
Publicado: (2016) -
The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
por: Bramlage, Peter, et al.
Publicado: (2015) -
Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice – study rationale and protocol of DIALOGUE
por: Gitt, Anselm K, et al.
Publicado: (2012) -
Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry
por: Schmieder, Roland E, et al.
Publicado: (2015) -
Azilsartan: Current Evidence and Perspectives in Management of Hypertension
por: Pradhan, Akshyaya, et al.
Publicado: (2019)